Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Psyence Biomedical Ltd. Warrant (PBMWW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: PBMWW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -85.19% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.15 | 52 Weeks Range 0.00 - 0.05 | Updated Date 06/28/2025 |
52 Weeks Range 0.00 - 0.05 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -54.2% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 71171 |
Shares Outstanding - | Shares Floating 71171 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Psyence Biomedical Ltd. Warrant
Company Overview
History and Background
Psyence Biomedical Ltd. is a life science biotechnology company focused on developing and commercializing naturally-derived psilocybin products for the global mental health crisis. The warrants provide the holder the right to purchase shares of Psyence Biomedical Ltd. stock at a specific price within a specified period.
Core Business Areas
- Psychedelic Drug Development: Focuses on the research and development of psilocybin-based therapies for mental health conditions.
Leadership and Structure
The information on Psyence Biomedical Ltd.'s leadership team can typically be found on their investor relations website. Organizational structure is likely a standard corporate model for a biotech company.
Top Products and Market Share
Key Offerings
- Psilocybin-based Therapies (Development Stage): Psyence Biomedical is focused on developing novel psilocybin therapies, currently in various stages of research and clinical trials. No products are yet commercialized. Competitors include Compass Pathways (CMPS), Atai Life Sciences (ATAI), and Mind Medicine (MNMD).
Market Dynamics
Industry Overview
The psychedelic medicine industry is an emerging market driven by the potential of psychedelic compounds like psilocybin to treat mental health disorders. It is characterized by increasing research, regulatory changes, and growing investor interest.
Positioning
Psyence Biomedical aims to be a leader in the psychedelic medicine space, focusing on developing and commercializing evidence-based psilocybin therapies. It competes with other biotech companies focused on psychedelic drugs.
Total Addressable Market (TAM)
The global market for mental health treatments is substantial, estimated to be billions of dollars annually. The TAM for psychedelic-assisted therapies is still developing, but is expected to reach multiple billions as research matures and regulatory approvals are obtained. Psyence is positioned to capture a portion of this emerging TAM.
Upturn SWOT Analysis
Strengths
- Focus on psilocybin-based therapies
- Experienced management team
- Strategic partnerships
Weaknesses
- Early stage of development (no commercialized products)
- High regulatory hurdles
- Limited financial resources relative to larger competitors
Opportunities
- Growing acceptance of psychedelic medicine
- Positive clinical trial results
- Strategic partnerships and acquisitions
Threats
- Regulatory setbacks
- Competition from larger pharmaceutical companies
- Negative publicity or safety concerns
Competitors and Market Share
Key Competitors
- CMPS
- ATAI
- MNMD
Competitive Landscape
Psyence Biomedical operates in a competitive landscape, where success depends on strong science, effective execution, and securing regulatory approval. The first mover advantage is significant.
Growth Trajectory and Initiatives
Historical Growth: Growth is based on the progress of their drug development pipeline.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization of their psilocybin therapies.
Recent Initiatives: Recent initiatives would likely involve clinical trial advancements, partnerships, and financing activities.
Summary
Psyence Biomedical is an early-stage biotech company in the emerging psychedelic medicine field. Its success hinges on the development and regulatory approval of its psilocybin-based therapies. It faces competition from larger, well-funded companies and regulatory hurdles, requiring strategic execution and capital management to achieve long-term growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Financial news sources
- Industry reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice. Investors should conduct their own due diligence before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Psyence Biomedical Ltd. Warrant
Exchange NASDAQ | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2024-01-26 | CEO & Director Dr. Neil Maresky M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 12 | Website https://www.psyencebiomed.com |
Full time employees 12 | Website https://www.psyencebiomed.com | ||
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.